Evidence map›Paper›PMID 33019495›Full record

ArticleInternational journal of molecular sciences2020

Inhibitory Effect of a Human MicroRNA, miR-6133-5p, on the Fibrotic Activity of Hepatic Stellate Cells in Culture.

Susumu Hamada-Tsutsumi, Masaya Onishi, Kentaro Matsuura, Masanori Isogawa, Keigo Kawashima, Yusuke Sato, Yasuhito Tanaka

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Identification and Validation of Hub Genes in Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2025
    Article
  2. Review
  3. Review
  4. Role of noncoding RNAs in liver fibrosis.World journal of gastroenterology · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Susumu Hamada-TsutsumiDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Masaya OnishiDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Kentaro MatsuuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Masanori IsogawaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.ORCID 0000-0001-8730-4303
Keigo KawashimaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Yusuke SatoLaboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.
Yasuhito TanakaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Nagoya City University · JPHokkaido University · JP

Funding

Research Program on Hepatitis from the Japan Agency for Medical Research and Development JP20fk0210048 and JP20fk0310101
6 · The paper itself

Abstract

backgroundWe recently identified 39 human microRNAs, which effectively suppress hepatitis B virus (HBV) replication in hepatocytes. Chronic HBV infection often results in active, hepatitis-related liver fibrosis; hence, we assessed whether any of these microRNAs have anti-fibrotic potential and predicted that miR-6133-5p may target several fibrosis-related genes.

methodsThe hepatic stellate cell line LX-2 was transfected with an miR-6133-5p mimic and subsequently treated with Transforming growth factor (TGF)-β. The mRNA and protein products of the

resultsThe expression of

conclusionmiR-6133-5p has a strong anti-fibrotic effect, mediated by inactivation of TGFBR2, Akt, and JNK.

Indexed as

ActinsAnthracenesCell DifferentiationCell Line, TransformedCell ProliferationCollagen Type ICollagen Type I, alpha 1 ChainFibroblastsGene Expression RegulationHepatic Stellate CellsHumansMAP Kinase Kinase 4MicroRNAsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3OligoribonucleotidesACTA2 protein, humanActinsAnthracenesCollagen Type ICollagen Type I, alpha 1 ChainFGFR1 protein, humanMAPK1 protein, humanMAPK3 protein, humanMAP Kinase Kinase 4MicroRNAsMIRN6133 microRNA, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3OligoribonucleotidesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktpyrazolanthroneReceptor, Fibroblast Growth Factor, Type 1Receptor, Transforming Growth Factor-beta Type IIRNA, Small InterferingTGFBR2 protein, humanTransforming Growth Factor betahepatic stellate cellsJNK signaling pathwayliver fibrosisTGF-β

Identifiers

PMID33019495
PMCPMC7583928
OpenAlexW3090050822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.